Your browser doesn't support javascript.
loading
Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial.
Yang, Xue; He, Zhiwei; Yuan, Li; Huang, Wenbin; Li, Doudou; Xiang, Pingping; Chen, Yu; Chen, Guofang; Liu, Chao.
Afiliação
  • Yang X; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • He Z; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Yuan L; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Huang W; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Li D; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Xiang P; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Chen Y; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Chen G; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Liu C; Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Profliuchao@163.com.
BMC Endocr Disord ; 23(1): 215, 2023 Oct 10.
Article em En | MEDLINE | ID: mdl-37814256

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Metformina Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: BMC Endocr Disord Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Metformina Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: BMC Endocr Disord Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China